[Translation] Study on the human bioequivalence of compound glycyrrhizin tablets
采用单中心、随机、开放、四周期完全重复交叉设计、单剂量设计比较空腹和餐后给药条件下,北京远方通达医药技术有限公司提供的复方甘草酸苷片(规格:每片含甘草酸单铵盐35 mg(甘草酸苷25 mg)、甘氨酸25 mg、DL-蛋氨酸25 mg)与Minophagen Pharmaceutical Co., Ltd.持证的复方甘草酸苷片(规格:每片含甘草酸单铵盐35 mg(甘草酸苷25 mg)、甘氨酸25 mg、DL-蛋氨酸25 mg;商品名:美能®/Stronger Neo-Minophagen C®)在健康人群中吸收程度和速度的差异,并评价北京远方通达医药技术有限公司提供的复方甘草酸苷片与与Minophagen Pharmaceutical Co., Ltd.持证的复方甘草酸苷片的安全性和耐受性
[Translation] Using a single-center, randomized, open, four-cycle fully repeated crossover design, and a single-dose design to compare fasting and postprandial administration conditions, the compound glycyrrhizin tablets (specifications: each tablet contains glycyrrhizic acid) provided by Beijing Yuanfang Tongda Pharmaceutical Technology Co., Ltd. Monoammonium salt 35 mg (glycyrrhizin 25 mg), glycine 25 mg, DL-methionine 25 mg) and compound glycyrrhizin tablets certified by Minophagegen Pharmaceutical Co., Ltd. (specifications: each tablet contains glycyrrhizin monoammonium salt 35 mg (glycyrrhizin 25 mg), glycine 25 mg, DL-methionine 25 mg; trade name: Stronger Neo-Minophagen C®) in healthy people, and evaluate the differences in absorption degree and speed of Beijing Yuanfang Tongda Medicine Safety and tolerability of compound glycyrrhizin tablets provided by Technology Co., Ltd. and compound glycyrrhizin tablets certified by Minophagen Pharmaceutical Co., Ltd.
100 Clinical Results associated with
0 Patents (Medical) associated with
100 Deals associated with
100 Translational Medicine associated with